After screening thousands of compounds, Stanford researchers identified an old antibiotic with an unusual ability: it could kill forms of Borrelia burgdorferi that survived exposure to doxycycline.

The drug is called azlocillin.

In laboratory experiments, azlocillin killed both actively growing Lyme bacteria and drug-tolerant forms of Borrelia. It also performed well in infected mice.

The finding, published in Scientific Reports in 2020, raised an intriguing possibility: perhaps drugs designed specifically to eliminate antibiotic-tolerant bacterial populations could eventually offer another treatment strategy for Lyme disease. (Nature)

But there is an important distinction.

Stanford did not demonstrate that azlocillin cures persistent Lyme symptoms in humans.

The research was preclinical.

What the scientists discovered was something potentially more foundational:

Standard Lyme antibiotics and alternative antibiotics may behave very differently against drug-tolerant forms of the Lyme bacterium.

That finding deserves attention.

Why Some People Don’t Fully Recover After Lyme Disease

Most people diagnosed with Lyme disease early and treated with recommended antibiotics improve.

But a subset of patients continue experiencing symptoms such as:

• profound fatigue
• muscle and joint pain
• neurological symptoms
• cognitive impairment
• reduced exercise tolerance
• difficulty returning to normal life

The condition is often described in research as post-treatment Lyme disease syndrome, or PTLDS.

Exactly why it occurs remains unresolved.

Stanford’s researchers described two major competing possibilities.

One hypothesis is that some Borrelia organisms enter a drug-tolerant state and survive antibiotic exposure.

Another is that the original infection triggers immune or inflammatory abnormalities that continue even after viable bacteria have been eliminated.

These possibilities are not necessarily mutually exclusive, and different patients could conceivably have different mechanisms.

Stanford researcher Jayakumar Rajadas summarized the uncertainty clearly: some scientists suspect persistent drug-tolerant bacteria; others suspect an immune disorder producing continuing inflammation. (Stanford Medicine)

That unresolved question is central to modern Lyme research.

If persistent symptoms are primarily driven by inflammation after bacterial eradication, giving more antibiotics may offer little benefit.

If viable bacteria remain in some patients, researchers need therapies capable of reaching and killing the organisms that conventional treatment missed.

That is where persister biology becomes important.

What Is a Persister Cell?

Persister cells are not necessarily antibiotic-resistant bacteria in the conventional sense.

Antibiotic resistance generally involves biological changes that allow bacteria to reproduce despite exposure to an antibiotic.

Persistence is different.

A fraction of bacteria can enter a low-activity physiological state that makes them less vulnerable to drugs designed to attack normal bacterial growth processes.

They essentially become harder to kill.

When the antibiotic pressure disappears, those surviving cells may become metabolically active again.

Research cited by the Stanford team had previously demonstrated that B. burgdorferi can form drug-tolerant persister populations in laboratory experiments. (Nature)

Importantly, Stanford’s investigators found that the surviving organisms in their experiments did not appear to have developed heritable antibiotic resistance. When the organisms were regrown and exposed again, they remained susceptible.

That supports the concept of drug tolerance rather than conventional genetic resistance. (Nature)

Stanford Screened 7,450 Compounds

The azlocillin discovery did not begin with researchers simply guessing which antibiotic might work.

The Stanford team used a drug-screening strategy.

Researchers screened 7,450 chemical compounds, roughly 80% of which were already FDA-approved drugs or compounds with existing pharmacological histories.

Approximately 300 initially showed activity.

Researchers then evaluated about 50 of the strongest candidates more closely.

Two antibiotics—azlocillin and cefotaxime—ultimately became the focus of the 2020 study because of their activity against Borrelia and their existing safety information. (Nature)

This strategy is known as drug repurposing.

Rather than beginning with a completely new molecule and spending years establishing its basic pharmacology, researchers investigate existing compounds to determine whether they have useful activity against another disease.

For a field with major unmet treatment needs, that can dramatically shorten the path between biological discovery and a potential therapeutic candidate.

Azlocillin Performed Differently From Doxycycline

Doxycycline remains one of the most commonly prescribed antibiotics for early Lyme disease.

In Stanford’s laboratory experiments, however, some B. burgdorferi cells survived exposure to doxycycline.

Researchers then took those doxycycline-tolerant organisms and exposed them to azlocillin.

The difference was substantial.

Azlocillin eliminated or dramatically reduced doxycycline-tolerant Borrelia populations in both actively growing cultures and stationary-phase cultures.

Across experiments, the researchers reported that azlocillin eliminated more than 99% of doxycycline-tolerant persisters under the conditions studied. (Nature)

In separate time-kill experiments, azlocillin reduced bacterial numbers progressively and ultimately eliminated detectable stationary-phase organisms at the concentrations tested after 96 hours. (Nature)

These are laboratory findings.

A bacterial culture is not a human body.

But scientifically, the finding matters because it demonstrates that failure of one antibiotic to eliminate a bacterial population does not necessarily mean that population is invulnerable.

A different drug may attack it through a different biological vulnerability.

Azlocillin and Cefotaxime Together Were Even More Effective

The researchers also tested combinations.

Azlocillin is a beta-lactam antibiotic that interferes with bacterial cell-wall synthesis.

Cefotaxime is another beta-lactam antibiotic.

When researchers combined the two drugs against doxycycline-tolerant B. burgdorferi, the combination was more effective under some experimental conditions than either drug alone.

One azlocillin-cefotaxime combination reduced surviving stationary-phase persister cells to fewer than 10 cells per milliliter in the laboratory model. (Nature)

The finding illustrates another important concept in infectious-disease research:

Combination therapy can sometimes attack a pathogen more effectively than a single drug.

This strategy is already fundamental in diseases ranging from tuberculosis to HIV.

Whether similar strategies will ultimately prove useful for selected Lyme patients remains a clinical research question.

Then Researchers Tested Azlocillin in Mice

A compound killing bacteria in a dish is interesting.

A compound working in an animal is more compelling.

Stanford therefore tested azlocillin in mice infected with B. burgdorferi.

The researchers evaluated treatment after different durations of infection and compared azlocillin with doxycycline and cefotaxime.

In the reported experiments, cultures taken from azlocillin-treated mice at later infection time points showed no B. burgdorferi growth in sampled ear tissue, while untreated control animals remained infected. Researchers also examined tissue using molecular methods. (Nature)

Stanford summarized the animal experiments by reporting that azlocillin eliminated the infection in its mouse model. (Stanford Medicine)

That moved azlocillin from an interesting screening hit to a legitimate preclinical drug candidate.

Why Azlocillin Was Especially Interesting

Azlocillin was not a newly invented experimental molecule.

It was an existing antibiotic with previous human use.

Stanford described it as FDA-approved but not commercially available for clinical use in the United States at the time of the research. The investigators hoped to reformulate the drug into an oral therapy specifically for Lyme disease. (Stanford Medicine)

Researchers Venkata Raveendra Pothineni and Jayakumar Rajadas also held intellectual property related to using the compound against Lyme disease.

The original scientific paper disclosed those patent interests. (Nature)

That is important context whenever promising academic research could ultimately become a commercial treatment.

It does not invalidate the findings.

It simply means the evidence should be evaluated independently and replicated.

The Bigger Scientific Question: Does Persistence Matter in Humans?

This is where the story becomes more complicated.

Demonstrating persisters in a laboratory model is not the same thing as demonstrating that persisters cause PTLDS in people.

The Stanford researchers themselves acknowledged this uncertainty.

Their experiment established that:

1. B. burgdorferi can exhibit drug-tolerant behavior under laboratory conditions.

2. Some organisms can survive doxycycline exposure in those models.

3. Azlocillin can kill many of those doxycycline-tolerant organisms.

4. Azlocillin demonstrated efficacy in infected mice.

What the study did not establish was:

1. That viable Borrelia persist in every person with post-treatment symptoms.

2. That persisters are the cause of PTLDS.

3. That azlocillin improves symptoms in human Lyme patients.

4. That azlocillin is superior to existing Lyme treatments in humans.

Those questions require clinical trials.

The authors themselves concluded that further investigation was necessary before the drug could be considered a Lyme therapy. (Nature)

The Human Trial Is the Critical Missing Step

When Stanford reported the research in March 2020, the team said it was working with a company to develop an oral formulation and planned to conduct a clinical trial. (Stanford Medicine)

That distinction matters enormously.

Promising therapies routinely work in bacterial cultures.

Fewer work in animals.

Fewer still prove safe and effective in rigorous human trials.

Human biology introduces complexities laboratory experiments cannot reproduce:

• drug absorption
• tissue penetration
• blood-brain barrier penetration
• metabolism
• immune-system interactions
• intracellular environments
• bacterial location within different tissues
• toxicity
• microbiome disruption
• co-infections
• differences between early and longstanding disease

A treatment capable of killing Borrelia in a culture dish still has to reach the relevant organism at an effective concentration inside the human body without creating unacceptable harm.

Until that is demonstrated, azlocillin remains a research candidate, not an established treatment for persistent Lyme disease.

But the Research Strategy May Be Even More Important Than the Drug

The most interesting part of the Stanford study may ultimately be its methodology.

Researchers began with a specific problem:

Some bacterial populations survive standard antibiotic exposure.

They then systematically screened thousands of compounds looking for molecules that behaved differently.

That is a fundamentally more powerful approach than repeatedly cycling through the same handful of antibiotics.

Modern drug discovery gives Lyme researchers tools that barely existed a generation ago:

high-throughput screening,

machine-learning-assisted compound selection,

genomics,

proteomics,

metabolomics,

advanced microscopy,

AI-driven drug repurposing,

and increasingly sophisticated animal and organoid models.

The question does not have to be:

“Which existing Lyme protocol should everyone receive?”

A better question is:

“What biological state is present in this particular patient, and which intervention specifically targets it?”

Lyme Treatment May Eventually Become Mechanism-Specific

The future of persistent Lyme disease may not be one universal therapy.

Patients who remain ill after treatment may ultimately fall into different biological subgroups.

One patient could have persistent inflammatory signaling.

Another could have autonomic dysfunction.

Another could have tissue damage from the original infection.

Another could have immune-mediated disease.

And if microbial persistence is eventually demonstrated to drive disease in a subset, those patients may require drugs specifically designed to eliminate persister organisms.

Those patients should not necessarily receive the same therapy.

That is why research like Stanford’s matters even before it produces an approved treatment.

It moves the field toward mechanism-specific medicine.

Azlocillin Is a Clue, Not Yet an Answer

It would be easy to read the Stanford headline and conclude that scientists discovered a cure for chronic Lyme disease.

They did not.

What they discovered was scientifically important but narrower:

Azlocillin showed unusually strong activity against Borrelia burgdorferi, including doxycycline-tolerant forms, in laboratory experiments and demonstrated efficacy in a mouse model of Lyme infection.

That is a meaningful result. (Nature)

It also raises questions worth pursuing.

Why could azlocillin kill organisms that survived doxycycline?

Which bacterial pathways made those cells vulnerable?

Could the drug reach relevant tissues in humans?

Would an oral formulation work?

Could biomarkers identify patients most likely to benefit?

And most importantly:

Would eliminating these organisms actually make persistently ill Lyme patients better?

That final question can only be answered in people.

Until then, azlocillin should neither be dismissed nor promoted as a proven treatment.

It should be investigated.

Because for the subset of Lyme patients who remain profoundly ill after conventional therapy, systematically searching for better answers is exactly what medical research should be doing.

Telos Lyme provides evidence-based educational information about Lyme and tick-borne disease research. This article does not recommend azlocillin or any other prescription therapy. Treatment decisions should be made with a qualified clinician, and experimental therapies should be evaluated through appropriately designed clinical research.